SOLBEC ANNOUNCES GRANT OF AUSTRALIAN PATENT
Summary:
· Solbec advises the granting of Australian patent, number 779512, entitled “Medicinal compositions and their method of
preparation”.
Perth, Australia. 14 June 2005. Solbec Pharmaceuticals (ASX: SBP) advises that the Australian patent, number 779512,
entitled “Medicinal compositions and their method of preparation” has been granted. This provides additional protection
to the Company’s lead compound Coramsine™. The term of the patent runs until April 2020.
The “Medicinal compositions” patent covers aspects of the manufacturing, purification process and formulation of the
active pharmaceutical ingredients of Coramsine™. It is the second Coramsine™ related patent application to be granted.
International cases of the application are ongoing.
Coramsine™ is now covered by seven families of patents / patent applications that are expected to provide protection
until 2023. They extend to clinical application, extraction and purification, the cell receptor involved in Coramsine™
selectivity, Coramsine’s™ effect on Interleukin-6 production, and Coramsine™ combination therapy.
Background Information
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better
therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key
project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a topical
treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of a plant
known as the Devil’s Apple (Solanum linnaeanum). They show activity against some cancers and cause potentially
therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential application in the areas
of animal health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final
stages of pre-commercial development and marketing.
www.solbec.com.au